Search Results

Your search for Thomas Powles, MD, MRCP matches 2 pages

Showing 1 - 2

By Matthew Stenger / Friday, April 28, 2017 10:37 AM

Second-Line Pazopanib vs Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer

A UK phase II trial comparing pazopanib (Votrient) with paclitaxel after failure of platinum-based therapy in patients with locally advanced or metastatic urothelial carcinoma was stopped early due to futility. These results were reported by Jones et al in the Journal of Clinical Oncology. Two...

bladder cancer

By The ASCO Post Staff / 2017 Genitourinary Cancers Symposium / Tuesday, February 21, 2017 9:48 AM

2017 GU Cancers Symposium: Updated Efficacy and Tolerability of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

At the 2017 Genitourinary Cancers Symposium, Powles et al presented updated efficacy and safety data for durvalumab in patients with locally advanced or metastatic urothelial cancer (Abstract 286). Updated results from the phase I/II trial showed an objective response rate of 20.4% in all...

Apr

Today In Oncology

Search Results

Your search for Thomas Powles, MD, MRCP matches 2 pages

Second-Line Pazopanib vs Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer

2017 GU Cancers Symposium: Updated Efficacy and Tolerability of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Comparative Effectiveness of Acupuncture vs Massage for Relieving Pain in Patients With Advanced Cancer

Risk of Second Primary Breast Cancer in Young Breast Cancer Survivors

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

Improving Early Detection of Pancreatic Cancer in High-Risk Patients

Survival Rates in Patients With Cancer and Intellectual and Developmental Disabilities